Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The cagrilintide + retatrutide stack covers four receptors but uses an investigational triple agonist instead of an approved drug
Existing patients moving states should update their address before the next refill so the platform can verify provider and pharmacy coverage
The short answer is yes, with the same caveats that apply to all tirzepatide treatment
Activate your own GLP-1 production instead of relying on injections Your intestine already produces GLP-1
Both medications can cause tiredness, though through different mechanisms
If you are weighing that, treat it as one option within a wider strategy, and talk with your clinician or pharmacist before adding anything while on GLP-1 therapy
